ProQR rises after AI drug discovery tie-up with Ginkgo Bioworks

Ginkgo Bioworks Holdings

08/04/2026 14:18

** Shares of biotech firm ProQR Therapeutics PRQR.O rise 5.8% to $1.80 premarket

** Co says it partnered with Ginkgo Bioworks DNA.N to speed up drug discovery using artificial intelligence

** Partnership gives ProQR access to Ginkgo’s automated lab platform, Nebula, to generate large amounts of experimental data more quickly, co says

** Co says the deal includes a strategic equity investment by Ginkgo, without disclosing financial terms

** ProQR aims to file a clinical trial application for its first AI‑discovered drug candidate by mid‑2026, with early patient data expected by year‑end - PRQR

** Co says it will outline its AI strategy and pipeline at a virtual investor event later on Tuesday

** Shares of Ginkgo Bioworks up 5% to $7.15 premarket

** As of last close, PRQR down ~19% YTD, DNA down ~18% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))